Metraipolis › archive › dc_3fea09f9d84f

Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety — Europe PMC PMID:41767371

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41767371
DOI
10.3389/fendo.2026.1735660
License (as archived)
solo-consultazione
Archived
2026-11-05T20:47:31.561Z
SHA-256 of the archived text
3ee087a46c66c1df4030899bfe17333060ae5e35a495245285125bd061e269ec
Stable URL of this page
https://metraipolis.com/documento/dc_3fea09f9d84f

How to cite

Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety — Europe PMC PMID:41767371 — Europe PMC (en), https://europepmc.org/article/MED/41767371 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3fea09f9d84f (Metraipolis archive dc_3fea09f9d84f, sha256 3ee087a46c66c1df4030899bfe17333060ae5e35a495245285125bd061e269ec)
BibTeX
@misc{dc3fea09f9d84f,
  title = {Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety — Europe PMC PMID:41767371},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41767371},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3fea09f9d84f; sha256 3ee087a46c66c1df4030899bfe17333060ae5e35a495245285125bd061e269ec},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41767371. Agents can read the archived copy with the MCP tool read_document.